Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) FCF Margin (2021 - 2025)

Inmune Bio's FCF Margin history spans 5 years, with the latest figure at 13648.0% for Q1 2025.

  • For Q1 2025, FCF Margin rose 3975200.0% year-over-year to 13648.0%; the TTM value through Sep 2025 reached 61688.0%, down 38086.0%, while the annual FY2024 figure was 238292.86%, 23056382.0% down from the prior year.
  • FCF Margin for Q1 2025 was 13648.0% at Inmune Bio, up from 53400.0% in the prior quarter.
  • Across five years, FCF Margin topped out at 3002.63% in Q1 2023 and bottomed at 127300.0% in Q1 2021.
  • The 5-year median for FCF Margin is 9916.28% (2023), against an average of 25645.8%.
  • The largest annual shift saw FCF Margin soared 12186135bps in 2022 before it tumbled -5039737bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 6000.0% in 2021, then rose by 2bps to 5871.13% in 2022, then tumbled by -107bps to 12146.43% in 2023, then tumbled by -340bps to 53400.0% in 2024, then surged by 74bps to 13648.0% in 2025.
  • Per Business Quant, the three most recent readings for INMB's FCF Margin are 13648.0% (Q1 2025), 53400.0% (Q1 2024), and 12146.43% (Q4 2023).